Page last updated: 2024-09-05

sb 203580 and puromycin aminonucleoside

sb 203580 has been researched along with puromycin aminonucleoside in 1 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (puromycin aminonucleoside)	Trials (puromycin aminonucleoside)	Recent Studies (post-2010) (puromycin aminonucleoside)
3,489	4	1,137	874	3	144

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agrawal, S; Benndorf, R; Guess, AJ; Manley, J; Mourey, RJ; Pengal, R; Ransom, RF; Smoyer, WE	1

Other Studies

1 other study(ies) available for sb 203580 and puromycin aminonucleoside

Article	Year
Inhibition of the protein kinase MK-2 protects podocytes from nephrotic syndrome-related injury. American journal of physiology. Renal physiology, 2011, Volume: 301, Issue:3 Topics: Animals; Cell Line; Disease Models, Animal; Heat-Shock Proteins; Imidazoles; Intracellular Signaling Peptides and Proteins; Mice; Molecular Chaperones; Neoplasm Proteins; Nephrotic Syndrome; p38 Mitogen-Activated Protein Kinases; Podocytes; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Puromycin Aminonucleoside; Pyridines; Serum Albumin; Signal Transduction	2011

Article

Year

Inhibition of the protein kinase MK-2 protects podocytes from nephrotic syndrome-related injury.

American journal of physiology. Renal physiology, 2011, Volume: 301, Issue:3

Topics: Animals; Cell Line; Disease Models, Animal; Heat-Shock Proteins; Imidazoles; Intracellular Signaling Peptides and Proteins; Mice; Molecular Chaperones; Neoplasm Proteins; Nephrotic Syndrome; p38 Mitogen-Activated Protein Kinases; Podocytes; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Puromycin Aminonucleoside; Pyridines; Serum Albumin; Signal Transduction

2011